Toby Maher, MD, PhD: Improving Lung Function with ENV-101 Treatment of Idiopathic Pulmonary Fibrosis; These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug's effect on individuals with IPF.

Media coverage

• Title	Toby Maher, MD, PhD: Improving Lung Function with ENV-101 Treatment of Idiopathic Pulmonary Fibrosis; These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug's effect on individuals with IPF.
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	20/05/24
  Persons	Michael Maher

• Title	Toby Maher, MD, PhD: Improving Lung Function with ENV-101 Treatment of Idiopathic Pulmonary Fibrosis
  Media name/outlet	HCP Live
  Country/Territory	United States
  Date	20/05/24
  Persons	Michael Maher